Cargando…
RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
Severe hemophilia is associated with spontaneous, prolonged and recurrent bleeding. Inadequate prevention and treatment of bleeding can lead to serious morbidity and mortality. Due to the limitations of intravenous clotting factor replacement, including the risk of inhibitory antibodies, innovative...
Autores principales: | Boyce, Sara, Rangarajan, Savita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132380/ https://www.ncbi.nlm.nih.gov/pubmed/37123985 http://dx.doi.org/10.2147/JBM.S390521 |
Ejemplares similares
-
Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort
por: Boyce, Sara, et al.
Publicado: (2022) -
An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
por: Machin, Nicoletta, et al.
Publicado: (2018) -
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020) -
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A
por: Lin, Wen-yi, et al.
Publicado: (2021) -
Treatment of hemophilia: a review of current advances and ongoing issues
por: Coppola, Antonio, et al.
Publicado: (2010)